Our initial indication is the Pancreatic ductal adenocarcinoma (PDAC). PDAC is one of the most difficult cancers to treat because its dense, fibrotic tumor microenvironment severely limits drug penetration. Studies suggest that only a small fraction of administered chemotherapy—often estimated around 1% — actually reaches the tumor, as abnormal vasculature, high interstitial pressure, and extensive stromal barriers restrict delivery. The remainder of 99% of chemotherapy circulates systemically, damaging healthy tissues and causing significant toxicities such as bone marrow suppression, neuropathy, and gastrointestinal injury.